Novo Nordisk A/S (NVO)
122.75
-1.78
(-1.43%)
USD |
NYSE |
Apr 18, 16:00
123.30
+0.55
(+0.45%)
Pre-Market: 06:51
Novo Nordisk Free Cash Flow: 10.16B for Dec. 31, 2023
Free Cash Flow Chart
Historical Free Cash Flow Data
Date | Value |
---|---|
December 31, 2023 | 10.16B |
September 30, 2023 | 11.76B |
June 30, 2023 | 9.713B |
March 31, 2023 | 9.409B |
December 31, 2022 | 9.092B |
September 30, 2022 | 7.739B |
June 30, 2022 | 8.391B |
March 31, 2022 | 9.284B |
December 31, 2021 | 7.577B |
September 30, 2021 | 6.278B |
June 30, 2021 | 5.340B |
March 31, 2021 | 4.935B |
December 31, 2020 | 4.577B |
September 30, 2020 | 7.055B |
June 30, 2020 | 7.060B |
March 31, 2020 | 5.511B |
December 31, 2019 | 5.331B |
September 30, 2019 | 5.583B |
June 30, 2019 | 4.762B |
March 31, 2019 | 5.013B |
December 31, 2018 | 5.102B |
September 30, 2018 | 4.741B |
June 30, 2018 | 5.386B |
March 31, 2018 | 4.593B |
December 31, 2017 | 4.950B |
Date | Value |
---|---|
September 30, 2017 | 5.902B |
June 30, 2017 | 5.837B |
March 31, 2017 | 6.504B |
December 31, 2016 | 5.952B |
September 30, 2016 | 5.776B |
June 30, 2016 | 5.544B |
March 31, 2016 | 5.178B |
December 31, 2015 | 4.743B |
September 30, 2015 | 4.753B |
June 30, 2015 | 5.048B |
March 31, 2015 | 4.785B |
December 31, 2014 | 4.884B |
September 30, 2014 | 4.655B |
June 30, 2014 | 3.700B |
March 31, 2014 | 3.478B |
December 31, 2013 | 3.971B |
September 30, 2013 | 3.312B |
June 30, 2013 | 3.461B |
March 31, 2013 | 3.417B |
December 31, 2012 | 3.211B |
September 30, 2012 | 3.517B |
June 30, 2012 | 3.720B |
March 31, 2012 | 3.431B |
December 31, 2011 | 3.370B |
September 30, 2011 | 3.596B |
Free Cash Flow Range, Past 5 Years
4.577B
Minimum
Dec 2020
11.76B
Maximum
Sep 2023
7.346B
Average
7.060B
Median
Jun 2020
Free Cash Flow Benchmarks
Amgen Inc | 7.359B |
AstraZeneca PLC | 6.567B |
Sanofi SA | -- |
Viking Therapeutics Inc | -73.38M |
Evaxion Biotech AS | -- |
Free Cash Flow Related Metrics
Cash from Operations (Quarterly) | 1.302B |
Cash from Investing (Quarterly) | -2.112B |
Cash from Financing (Quarterly) | -1.424B |
Free Cash Flow Per Share (Quarterly) | -0.238 |
Free Cash Flow to Equity (Quarterly) | -465.86M |
Free Cash Flow to Firm (Quarterly) | -959.66M |
Free Cash Flow Yield | 1.84% |